BC Week In Review | Feb 18, 2013
Company News

Xenon management update

Xenon Pharmaceuticals Inc. , Burnaby, B.C.   Business: Pharmacogenetics, Neurology, Endocrine/Metabolic   Hired: Gary Bridger as EVP of R&D, formerly CSO of AnorMed Inc. , which the Genzyme Corp. unit of Sanofi acquired  ...
BC Week In Review | May 23, 2011
Company News

Poniard cancer news

Poniard disclosed in its 1Q11 earnings that it will require additional capital to continue operations through 4Q11. Last year, Poniard said it hired Leerink Swann to seek strategic alternatives, including financing, merger, sale or partnership,...
BC Week In Review | Jun 14, 2010
Clinical News

Picoplatin: Final Phase III data

Final data from the open-label, international Phase III SPEAR trial in 401 patients showed that IV picoplatin once every 3 weeks plus best supportive care (BSC) had a median OS of 20.6 weeks vs. 19.7...
BC Week In Review | Mar 29, 2010
Company News

Poniard cancer news

Poniard said it hired Leerink Swann to seek strategic alternatives, including financing, merger, sale or partnership, and plans to restructure and reduce headcount by 10 (45%) to 12, effective April 30. The move follows the...
BC Week In Review | Mar 15, 2010
Clinical News

Picoplatin: Additional Phase II data

Additional data from a Phase II trial in 29 evaluable patients showed that picoplatin in combination with docetaxel and prednisone led to a median OS of 21.4 months compared to 18.9 months for patients who...
BC Week In Review | Feb 1, 2010
Clinical News

Picoplatin: Final Phase II data

Final data from a Phase II trial in 101 chemotherapy-naïve patients showed that IV picoplatin plus 5-fluorouracil (5-FU) and leucovorin met the primary endpoint of significantly reducing neurotoxicity vs. oxaplatin plus 5-FU and leucovorin (p<0.004)....
BC Week In Review | Dec 7, 2009
Company News

Inimex management update

Inimex Pharmaceuticals Inc. , Burnaby, B.C.   Business: Infectious, Autoimmune   Hired: Michael Abrams as president and CEO, formerly president and CEO of AnorMed Inc. (now a part of Genzyme Corp. ); he replaces John North,...
BC Extra | Nov 24, 2009
Company News

Inimex names Abrams CEO

Infectious disease and autoimmune company Inimex Pharmaceuticals Inc . (Burnaby, B.C.) hired Michael Abrams as president, CEO and a director. Abrams is the former president and CEO of AnorMed Inc ., which was acquired by Genzyme...
BC Week In Review | Nov 23, 2009
Clinical News

Picoplatin: Additional Phase II data

Additional data from a Phase II trial in 101 chemotherapy-naïve patients showed the IV picoplatin led to a 1-year survival rate of 52% vs. 55% for oxaliplatin. The company twice previously reported data showing that...
BC Week In Review | Nov 23, 2009
Clinical News

Picoplatin: Phase III data

The open-label, international Phase III SPEAR trial in 401 patients showed that IV picoplatin once every 3 weeks plus best supportive care missed the primary endpoint of significantly improving OS vs. best supportive care alone...
Items per page:
1 - 10 of 233
BC Week In Review | Feb 18, 2013
Company News

Xenon management update

Xenon Pharmaceuticals Inc. , Burnaby, B.C.   Business: Pharmacogenetics, Neurology, Endocrine/Metabolic   Hired: Gary Bridger as EVP of R&D, formerly CSO of AnorMed Inc. , which the Genzyme Corp. unit of Sanofi acquired  ...
BC Week In Review | May 23, 2011
Company News

Poniard cancer news

Poniard disclosed in its 1Q11 earnings that it will require additional capital to continue operations through 4Q11. Last year, Poniard said it hired Leerink Swann to seek strategic alternatives, including financing, merger, sale or partnership,...
BC Week In Review | Jun 14, 2010
Clinical News

Picoplatin: Final Phase III data

Final data from the open-label, international Phase III SPEAR trial in 401 patients showed that IV picoplatin once every 3 weeks plus best supportive care (BSC) had a median OS of 20.6 weeks vs. 19.7...
BC Week In Review | Mar 29, 2010
Company News

Poniard cancer news

Poniard said it hired Leerink Swann to seek strategic alternatives, including financing, merger, sale or partnership, and plans to restructure and reduce headcount by 10 (45%) to 12, effective April 30. The move follows the...
BC Week In Review | Mar 15, 2010
Clinical News

Picoplatin: Additional Phase II data

Additional data from a Phase II trial in 29 evaluable patients showed that picoplatin in combination with docetaxel and prednisone led to a median OS of 21.4 months compared to 18.9 months for patients who...
BC Week In Review | Feb 1, 2010
Clinical News

Picoplatin: Final Phase II data

Final data from a Phase II trial in 101 chemotherapy-naïve patients showed that IV picoplatin plus 5-fluorouracil (5-FU) and leucovorin met the primary endpoint of significantly reducing neurotoxicity vs. oxaplatin plus 5-FU and leucovorin (p<0.004)....
BC Week In Review | Dec 7, 2009
Company News

Inimex management update

Inimex Pharmaceuticals Inc. , Burnaby, B.C.   Business: Infectious, Autoimmune   Hired: Michael Abrams as president and CEO, formerly president and CEO of AnorMed Inc. (now a part of Genzyme Corp. ); he replaces John North,...
BC Extra | Nov 24, 2009
Company News

Inimex names Abrams CEO

Infectious disease and autoimmune company Inimex Pharmaceuticals Inc . (Burnaby, B.C.) hired Michael Abrams as president, CEO and a director. Abrams is the former president and CEO of AnorMed Inc ., which was acquired by Genzyme...
BC Week In Review | Nov 23, 2009
Clinical News

Picoplatin: Additional Phase II data

Additional data from a Phase II trial in 101 chemotherapy-naïve patients showed the IV picoplatin led to a 1-year survival rate of 52% vs. 55% for oxaliplatin. The company twice previously reported data showing that...
BC Week In Review | Nov 23, 2009
Clinical News

Picoplatin: Phase III data

The open-label, international Phase III SPEAR trial in 401 patients showed that IV picoplatin once every 3 weeks plus best supportive care missed the primary endpoint of significantly improving OS vs. best supportive care alone...
Items per page:
1 - 10 of 233